Table I.
Survival analysis of the CXCR subunit expression levels in patients with early-stage PDAC.
| OS | DFS | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subunit | MST | P-value | HR crude (95% CI) | P-value | Coefficient Ba | HR adjusted (95% CI)b | P-value | MRT | P-value | HR crude (95%CI) | P-value | Coefficient Ba | HR adjusted (95% CI)b | P-value |
| CXCR1 | 0.654 | |||||||||||||
| Low | 511 | Ref. | 0.654 | Ref. | 0.290 | 593 | 0.466 | Ref. | 0.467 | Ref. | 0.124 | |||
| High | 518 | 0.90 (0.55-1.45) | −0.110 | 0.75 (0.44-1.28) | 716 | 0.78 (0.40-1.52) | −0.248 | 0.55 (0.25-1.18) | ||||||
| CXCR2 | 0.056 | |||||||||||||
| Low | 476 | Ref. | 0.058 | Ref. | 0.150 | 581 | 0.006 | Ref. | 0.008 | Ref. | 0.008 | |||
| High | 596 | 0.63 (0.39-1.02) | −0.469 | 0.66 (0.38-1.16) | 872 | 0.39 (0.20-0.78) | −0.939 | 0.32 (0.14-0.74) | ||||||
| CXCR3 | 0.033 | |||||||||||||
| Low | 393 | Ref. | 0.035 | Ref. | 0.071 | 716 | 0.500 | Ref. | 0.501 | Ref. | 0.292 | |||
| High | 603 | 0.59 (0.37-0.97) | −0.522 | 0.61 (0.36-1.04) | 620 | 0.78 (0.39-1.59) | −0.243 | 0.65 (0.30-1.45) | ||||||
| CXCR4 | 0.018 | |||||||||||||
| Low | 473 | Ref. | 0.019 | Ref. | 0.023 | 593 | 0.543 | Ref. | 0.544 | Ref. | 0.692 | |||
| High | 592 | 0.56 (0.34-0.91) | −0.586 | 0.51 (0.28-0.91) | 620 | 0.81 (0.41-1.59) | −0.208 | 0.84 (0.36-1.96) | ||||||
| CXCR5 | 0.231 | |||||||||||||
| Low | 593 | Ref. | 0.233 | Ref. | 0.405 | 461 | 0.057 | Ref. | 0.062 | Ref. | 0.412 | |||
| High | 517 | 0.74 (0.46-1.21) | −0.296 | 0.79 (0.45-1.38) | 872 | 0.50 (0.24-1.04) | −0.694 | 0.71 (0.31-1.62) | ||||||
| CXCR6 | 0.005 | |||||||||||||
| Low | 458 | Ref. | 0.005 | Ref. | 0.025 | 443 | 0.027 | Ref. | 0.030 | Ref. | 0.237 | |||
| High | 603 | 0.49 (0.30-0.80) | −0.715 | 0.53 (0.31-0.92) | 831 | 0.44 (0.21-0.93) | −0.819 | 0.60 (0.26-1.40) | ||||||
a
B, regression coefficient calculated using univariate Cox proportional hazards regression analysis.
b
Adjusted for pathological stage T and N stage, histological grade, radical resection and targeted molecular therapy. CXCR, C-X-C motif chemokine receptor; TCGA, The Cancer Genome Atlas; PDAC, pancreatic ductal adenocarcinoma; OS, overall survival time; DFS, disease-free survival time; MST, median survival time; MRT, median disease-free survival time; HR, hazard ratio; CI, confidence interval; Ref., reference.